Cradle Enhances Antibody Discovery for Autoimmune Diseases in Partnership with Argenx

Cradle's Boost in Antibody Discovery for Autoimmune Diseases



Cradle, a pioneering company in protein engineering, has recently expanded its collaboration with Argenx, a global leader in antibody development. This partnership focuses on enhancing the discovery of antibodies aimed at treating autoimmune diseases through Cradle's advanced AI-driven platform. As part of this collaboration, more scientists at Argenx will gain access to Cradle's comprehensive protein engineering solutions, significantly broadening their research capabilities.

The journey began with impressive results from initial antibody discovery programs. Cradle's end-to-end platform has already proven instrumental in optimizing existing antibody candidates and generating new ones that exhibit desirable properties, such as greater target affinity and selectivity. The collaborative efforts have led to successive rounds of design, testing, and evaluation, positioning Argenx to push the boundaries of traditional antibody discovery methods.

"The essence of advancing our understanding and development of antibodies lies in our ability to deliver better medicines to those in need swiftly," expressed Bas Van Der Woning, the Head of Discovery at Argenx. The use of Cradle's AI platform has allowed their scientists to delve into innovative design strategies far beyond their initial candidates. Each experimental round leads to enhanced insights, enabling Argenx to refine their antibody designs progressively.

As Cradle's platform becomes more accessible to various discovery teams at Argenx, the expectations for its application across multiple antibody development programs are high. This collaboration is a crucial step for Argenx as they aim to transform immunology discoveries into effective antibody-based therapeutics.

Stef van Grieken, the CEO and co-founder of Cradle, couldn't hide his excitement about the partnership. He emphasized, "Argenx is at the forefront of antibody innovation, and witnessing more of their scientists utilize our platform marks a significant milestone. We're committed to empowering researchers who are most familiar with the biology, enhancing our collaborative efforts with each experiment that they conduct."

Cradle’s platform uniquely integrates various facets of protein engineering, showcasing its capability to guide scientists through the entire lifecycle of antibody design and candidate selection. With features like AI-driven engineering, active learning from experimental outcomes, and multi-property optimization, the platform is highly regarded across numerous active research and development programs globally.

Currently, Cradle serves a growing list of clients spanning across the pharmaceutical, industrial biotechnology, agriculture, and consumer goods sectors, with over 80 ongoing research and development initiatives worldwide. Their headquarters are located in Amsterdam, the Netherlands, while they also maintain a presence in Zurich, Switzerland, and the United States. Backed by reputable investors such as IVP, Index Ventures, and Kindred Capital, Cradle’s innovative approach continues to attract interest and support from notable industry players.

In conclusion, the enhanced collaboration between Cradle and Argenx represents a vital leap toward advancing medical treatments for autoimmune diseases. Through the synergy of Cradle's AI-powered platform and Argenx’s cutting-edge research, the future of antibody discovery looks promising, with the potential for groundbreaking therapies on the horizon.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.